Calamos Advisors
ITCI icon

Calamos Advisors’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Calamos Advisors’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-27,668
Closed -$2.31M – 998
2024
Q4 		$2.31M Sell
27,668
-3,952
-12% -$325K 0.01% 597
2024
Q3 		$2.31M Buy
31,620
+15,216
+93% +$1.14M 0.01% 598
2024
Q2 		$1.12M Buy
16,404
+7,590
+86% +$526K 0.01% 636
2024
Q1 		$610K Buy
8,814
+662
+8% +$45.5K ﹤0.01% 692
2023
Q4 		$584K Buy
+8,152
New +$469K ﹤0.01% 718
2022
Q3 		– Sell
-93,772
Closed -$5.35M – 1353
2022
Q2 		$5.35M Sell
93,772
-4,940
-5% -$280K 0.02% 670
2022
Q1 		$6.04M Buy
+98,712
New +$5.13M 0.02% 646

Other funds holding ITCI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Pentwater Capital Management
Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return
HBK Investments
HBK Investments Dallas, Texas $10.3B AUM 67.69% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Davidson Kempner Capital Management
Davidson Kempner Capital Management New York $8.42B AUM 61.81% 1-Year Est. Return
UBS O'Connor
UBS O'Connor Chicago, Illinois $3.76B AUM 62.41% 1-Year Est. Return
Farallon Capital Management
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

Calamos Advisors's ITCI Position: Q1 2025 in Review

Calamos Advisors sold out of Intra-Cellular Therapies Inc. (ITCI) in Q1 2025, closing a stake of 27,668 shares — an estimated $2.31M sold.

Calamos Advisors first reported a position in ITCI in Q1 2022 and held it in 7 quarters. The position peaked at $6.04M in Q1 2022. 395 funds tracked by Wall St. Rank hold ITCI as of Q1 2025.

  • Calamos Advisors reported no remaining Intra-Cellular Therapies Inc. position as of Q1 2025 after selling out during the quarter.
  • Calamos Advisors sold 27,668 Intra-Cellular Therapies Inc. shares in Q1 2025, an estimated $2.31M.
  • Calamos Advisors first reported a position in Intra-Cellular Therapies Inc. in Q1 2022 and held it in 7 quarters.
  • Calamos Advisors's Intra-Cellular Therapies Inc. position peaked at $6.04M in Q1 2022.
  • 395 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q1 2025.

Based on Calamos Advisors's 13F filing for Q1 2025, filed 29 Apr 2025.